AstraZeneca Expands Mississauga, Ontario, Canada, Research-Development Campus
02/28/2023
The R&D Hub focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.
"Our investment in the AstraZeneca R&D Hub and Alexion Development Hub will play a critical role in the development of new and innovative medicines aimed at treating, preventing and, in the future, potentially even curing complex diseases like cancer and rare diseases," said Kiersten Combs, President, AstraZeneca Canada.
The Mississauga-based Hub has doubled in size since 2019 and is currently leading more than 120 oncology and biopharmaceutical global clinical studies, involving patients in 50+ countries.
"Through Taking Life Sciences to the Next Level, Ontario's life sciences strategy, our government is building a more competitive Ontario with a stronger life sciences sector. AstraZeneca's transformative investment and new global clinical research centre will create hundreds of new jobs, while helping to ensure that our province remains a global leader in innovation and the life sciences sector. Thank you, AstraZeneca, for choosing Ontario,” noted Vic Fedeli, Minister of Economic Development, Job Creation and Trade.
Cambridge, England-based AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. The company has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation and has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.
"Invest Ontario congratulates AstraZeneca on this significant new investment which will drive innovation and increase the capacity for clinical trial management in Ontario. Invest Ontario is committed to attracting investments that further accelerate the growth of Life Sciences and solidify our position as a global leader in the industry,” Trevor Dauphinee, CEO of Invest Ontario added.
Project Announcements
Blue Buffalo Expands Richmond, Indiana, Production Complex
03/24/2023
Schrödinger Expands New York, New York, Research Operations
03/23/2023
Cirba Solutions Plans Richland County, South Carolina, Lithium-ion Battery Materials Campus
03/23/2023
Albemarle Corporation Plans Chester County, South Carolina, Lithium Hydroxide Processing Plant
03/23/2023
Tillamook County Creamery Association Plans Decatur, Illinois, Ice Cream Manufacturing Plant
03/23/2023
ENTEK Plans Terre Haute, Indiana, ‘Wet-Process’ Lithium-ion Battery Plant
03/23/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
19th Annual Consultants Survey: Clients Challenged by Tight Labor Market, Energy Availability
Q1 2023
-
The Top Investment Location Prospects for Aerospace Manufacturing
Q1 2023
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
How Are Economic Developers Partnering to Solve Workforce Challenges?
Q1 2023
-
Strategies to Overcome Intensifying Industrial Real Estate Challenges
Q1 2023